Showing 1 - 7 results of 7 for search 'Jaroslava Voglová', query time: 0.03s Refine Results
  1. 1
    Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

    Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML) by Ladislav Chrobák, Jaroslava Voglová

    Published 2003-01-01
    Get full text
    Article
  2. 2
    Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone

    Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone by Petra Bělohlávková, Vladimír Maisnar, Jaroslava Voglová, Tomáš Buchler, Pavel Žák

    Published 2016-08-01
    Get full text
    Article
  3. 3
    Effects of Repeated Administration of Dithiol Chelating Agent - Sodium 2,3-Dimercapto-1-propanesulphonate (DMPS) - On Biochemical and Haematological Parameters in Rabbits

    Effects of Repeated Administration of Dithiol Chelating Agent - Sodium 2,3-Dimercapto-1-propanesulphonate (DMPS) - On Biochemical and Haematological Parameters in Rabbits by Vladimír Geršl, Radomír Hrdina, Jaroslava Vávrová, Magdalena Holečková, Vladimír Palička, Jaroslava Voglová, Yvona Mazurová, Jiří Bajgar

    Published 1997-01-01
    Get full text
    Article
  4. 4
    The Effects of Subchronical Exposure to SO2 on Biochemical and Hematological Parameters in Guinea Pigs

    The Effects of Subchronical Exposure to SO2 on Biochemical and Hematological Parameters in Guinea Pigs by Jana Suchánková, Peter Višňovský, Vladimír Geršl, Zdeněk Fiala, Yvona Mazurová, Vladimír Palička, Jaroslava Vávrová, Jaroslava Voglová

    Published 1997-01-01
    Get full text
    Article
  5. 5
    The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

    The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients by Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, Zdenek Racil, Daniela Zackova, Katerina Hrochova, Jana Malakova, Jiri Mayer, Pavel Zak

    Published 2018-02-01
    Get full text
    Article
  6. 6
    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

    Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. by Anna Kreutzman, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglová, Marjatta Sinisalo, Emília Flochová, Jukka Vakkila, Petteri Arstila, Kimmo Porkka, Satu Mustjoki

    Published 2011-01-01
    Get full text
    Article
  7. 7
    P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

    P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE by Lukas Semerad, Daniela Žáčková, Petra Belohlavkova, Jaroslava Voglova, Pavel Žák, Edgar Faber, Tomas Papajik, Ivana Skoumalova, Michal Karas, Pavel Jindra, Hana Klamová, Cyril Salek, Dana Srbová, Hana Zizkova, Lukas Stejskal, Olga Cerna, Eduard Cmunt, Petra Cicatkova, Anezka Kvetkova, Tomas Hornak, Ivana Jeziskova, Tomas Jurcek, Barbora Weinbergerová, Jirina Prochazkova, Katerina Machova Polakova, Adam Svobodnik, Radka Stepanova, Jiri Mayer

    Published 2023-08-01
    Get full text
    Article

Search Tools: